Approval of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Microcap 250 and 5.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenotech Laboratories' Board approved standalone unaudited results for Q2 FY26 and H1 FY26, with a clean (unmodified) limited review report from auditor GSKA & Co. Revenue from operations rose to Rs 1,023.19 lakh in Q2 (up about 17% YoY from Rs 874.60 lakh) and to Rs 1,887.10 lakh for H1 FY26 (up about 7% YoY from Rs 1,764.09 lakh). Despite revenue growth, the company posted a standalone loss of Rs 83.65 lakh in Q2 FY26 against a profit of Rs 134.74 lakh a year ago, and H1 FY26 profit collapsed to just Rs 15.30 lakh from Rs 263.71 lakh in H1 FY25. The sharp drop is largely driven by a one-time tax adjustment of Rs 190.49 lakh related to switching to the concessional tax regime under Section 115BAA, reversal of Rs 187.47 lakh MAT credit, and Rs 157.82 lakh deferred tax charge on unabsorbed depreciation. Operating cash flow remained healthy at Rs 832.89 lakh for H1 (vs Rs 337.31 lakh YoY).
Revenue growth is encouraging, but the headline Q2 loss and steep PAT decline — though largely non-cash and one-off in nature — could pressure short-term sentiment. The shift to the lower tax regime should support future earnings, while zero borrowings and strong cash position keep the balance sheet healthy.